In the latest development in the evolving landscape of laboratory developed tests (LDTs), the Food and Drug Administration (FDA) has issued its much-anticipated proposed rule. The rule, affecting part 809 of title 21 of the Code of Federal Regulations (21 CFR), states explicitly that in vitro diagnostics (IVDs) are considered medical devices, even when these are developed and manufactured within a laboratory setting.
This robotic regulation change comes at a critical stage in the application of LDTs as tools of precision medicine. The classification of IVDs as medical devices thus has the potential to shape the overall approach to regulatory oversight and control.
On October 31, the FDA held a webinar to provide a deeper dive into its proposed rule, namely 21 C.F.R, § 809.3.
The proposed rule and public dialogue form the next phase of a process that has been charted by multiple challenges and debates over the course of recent history. This pivotal change in regulations, and hence oversight, promises to bring about a fresh perspective in the realm of IVDs and LDTs.
The full impact of this regulatory shift may only unfold over time. However, legal professionals, healthcare providers, and industry stakeholders will all be keeping a close eye on developments and eagerly awaiting feedback from the legal community and industry responses in the months to come.
To read more about this significant update and proposed rule in detail, visit the full text of the article here.